logo
Sign In
    Farxiga vs. GlyxambiBerinert vs. CinryzeEmgality vs. QuliptaFarxiga vs. InvokanaFirazyr vs. SajazirGlyxambi vs. InvokanaInvokamet vs. SynjardyOpzelura vs. DupixentOrencia vs. RinvoqQulipta vs. VyeptiStelara vs. TremfyaSynjardy vs. VictozaTaltz vs. BimzelxVyepti vs. Nurtec ODTView all Comparisons
    ADHD drugsAnxiety drugsAsthma drugsAtopic dermatitis drugsDepression drugsHeart failure drugsHypertension drugsLymphoma drugsOsteoarthritis drugsRheumatoid arthritis drugsRosacea drugsSchizophrenia drugsType 2 Diabetes drugsView all Indications
    Bayer drugsAbbVie drugsAstraZeneca drugsEli Lilly and Company drugsGenetech drugsGlaxoSmithKline (GSK) drugsNovartis drugsPfizer drugsTakeda Pharmaceuticals drugsTeva Pharmaceuticals drugsAmgen drugsView all Manufacturers
    Beta-Adrenergic BlockerAngiotensin Converting Enzyme InhibitorAngiotensin 2 Receptor BlockerCalcium Channel BlockerDiureticsHMG-CoA Reductase InhibitorProton Pump InhibitorSelective Serotonin Reuptake InhibitorNorepinephrine Reuptake InhibitorBenzodiazepinesOpioid AgonistsNonsteroidal Anti-inflammatory DrugsAntiepileptic AgentsAntipsychoticsAntihistaminesView all Classes
    Wegovy®Ozempic®Mounjaro®Zepbound®Jardiance®Farxiga®Dupixent®Trulicity®Lyrica®Lipitor®Effexor®Concerta®Depakote®Trintellix®Rexulti®Rinvoq®Verzenio®Taltz®
    For ProvidersRequest DemoJoin Research Panel
    For BusinessHCP ChannelCommercial O/SEngageMarketplaceOneHubInsight
    Tools & MorePrescribing InfoCoverageSavingsPatient ResourcesA-Z IndicationsCompare Drugs
    CompanyAboutInsightsCareersContact
    Legit Script Certified
    Get the latest insights in your inbox
    Follow us
    Legit Script Certified
    • Terms and Conditions
    • Privacy Policy
    • © 2025 PrescriberPoint. All Rights Reserved.

    Drugs interactions for

    • 0 Major drug interactions
    • 1 Moderate drug interactions (including ingredients like Pozelimab)
    • 159 Minor drug interactions (including ingredients like Adalimumab, Aducanumab, Alemtuzumab)
    160 interactions for
    A therapy excluded from this list of known interactions does not necessarily mean that no interactions exist between that therapy and and .
    Pozelimab
    The serum concentration of Pozelimab can be decreased when it is combined with Galcanezumab.
    Adalimumab
    The risk or severity of adverse effects can be increased when Adalimumab is combined with Galcanezumab.
    Aducanumab
    The risk or severity of adverse effects can be increased when Aducanumab is combined with Galcanezumab.
    Alemtuzumab
    The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Galcanezumab.
    Alirocumab
    The risk or severity of adverse effects can be increased when Alirocumab is combined with Galcanezumab.
    Amivantamab
    The risk or severity of adverse effects can be increased when Galcanezumab is combined with Amivantamab.
    Anifrolumab
    The risk or severity of adverse effects can be increased when Anifrolumab is combined with Galcanezumab.
    Ansuvimab
    The risk or severity of adverse effects can be increased when Galcanezumab is combined with Ansuvimab.
    Anthrax immune globulin human
    The risk or severity of adverse effects can be increased when Anthrax immune globulin human is combined with Galcanezumab.
    Antilymphocyte immunoglobulin (horse)
    The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin (horse) is combined with Galcanezumab.
    Antithymocyte immunoglobulin (rabbit)
    The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Galcanezumab.
    Asfotase alfa
    The risk or severity of adverse effects can be increased when Asfotase alfa is combined with Galcanezumab.
    Atezolizumab
    The risk or severity of adverse effects can be increased when Atezolizumab is combined with Galcanezumab.
    Atoltivimab
    The risk or severity of adverse effects can be increased when Galcanezumab is combined with Atoltivimab.
    Avelumab
    The risk or severity of adverse effects can be increased when Avelumab is combined with Galcanezumab.
    Axatilimab
    The risk or severity of adverse effects can be increased when Galcanezumab is combined with Axatilimab.
    Bamlanivimab
    The risk or severity of adverse effects can be increased when Galcanezumab is combined with Bamlanivimab.
    Basiliximab
    The risk or severity of adverse effects can be increased when Basiliximab is combined with Galcanezumab.
    Belimumab
    The risk or severity of adverse effects can be increased when Belimumab is combined with Galcanezumab.
    Benralizumab
    The risk or severity of adverse effects can be increased when Benralizumab is combined with Galcanezumab.
    Bevacizumab
    The risk or severity of adverse effects can be increased when Bevacizumab is combined with Galcanezumab.
    Bezlotoxumab
    The risk or severity of adverse effects can be increased when Bezlotoxumab is combined with Galcanezumab.
    Bimekizumab
    The risk or severity of adverse effects can be increased when Bimekizumab is combined with Galcanezumab.
    Blinatumomab
    The risk or severity of adverse effects can be increased when Blinatumomab is combined with Galcanezumab.
    Brentuximab vedotin
    The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Galcanezumab.
    Brodalumab
    The risk or severity of adverse effects can be increased when Brodalumab is combined with Galcanezumab.
    Brolucizumab
    The risk or severity of adverse effects can be increased when Galcanezumab is combined with Brolucizumab.
    Burosumab
    The risk or severity of adverse effects can be increased when Burosumab is combined with Galcanezumab.
    Canakinumab
    The risk or severity of adverse effects can be increased when Canakinumab is combined with Galcanezumab.
    Caplacizumab
    The risk or severity of adverse effects can be increased when Caplacizumab is combined with Galcanezumab.
    Cemiplimab
    The risk or severity of adverse effects can be increased when Galcanezumab is combined with Cemiplimab.
    Certolizumab pegol
    The risk or severity of adverse effects can be increased when Certolizumab pegol is combined with Galcanezumab.
    Cetuximab
    The risk or severity of adverse effects can be increased when Cetuximab is combined with Galcanezumab.
    Cilgavimab
    The risk or severity of adverse effects can be increased when Galcanezumab is combined with Cilgavimab.
    Clesrovimab
    The risk or severity of adverse effects can be increased when Galcanezumab is combined with Clesrovimab.
    Conjugated estrogens
    Conjugated estrogens may increase the thrombogenic activities of Galcanezumab.
    Cosibelimab
    The risk or severity of adverse effects can be increased when Galcanezumab is combined with Cosibelimab.
    Crovalimab
    The risk or severity of adverse effects can be increased when Galcanezumab is combined with Crovalimab.
    Daratumumab
    The risk or severity of adverse effects can be increased when Daratumumab is combined with Galcanezumab.
    Denosumab
    The risk or severity of adverse effects can be increased when Denosumab is combined with Galcanezumab.
    Digoxin Immune Fab (Ovine)
    The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Galcanezumab.
    Dinutuximab
    The risk or severity of adverse effects can be increased when Dinutuximab is combined with Galcanezumab.
    Donanemab
    The risk or severity of adverse effects can be increased when Galcanezumab is combined with Donanemab.
    Dostarlimab
    The risk or severity of adverse effects can be increased when Galcanezumab is combined with Dostarlimab.
    Dulaglutide
    The risk or severity of adverse effects can be increased when Dulaglutide is combined with Galcanezumab.
    Dupilumab
    The risk or severity of adverse effects can be increased when Dupilumab is combined with Galcanezumab.
    Durvalumab
    The risk or severity of adverse effects can be increased when Durvalumab is combined with Galcanezumab.
    Ebola Zaire vaccine (live, attenuated)
    The therapeutic efficacy of Ebola Zaire vaccine (live, attenuated) can be decreased when used in combination with Galcanezumab.
    Eculizumab
    The risk or severity of adverse effects can be increased when Eculizumab is combined with Galcanezumab.
    Eflapegrastim
    The risk or severity of adverse effects can be increased when Galcanezumab is combined with Eflapegrastim.
    Eftrenonacog alfa
    The risk or severity of adverse effects can be increased when Eftrenonacog alfa is combined with Galcanezumab.
    Elotuzumab
    The risk or severity of adverse effects can be increased when Elotuzumab is combined with Galcanezumab.
    Emapalumab
    The risk or severity of adverse effects can be increased when Galcanezumab is combined with Emapalumab.
    Emicizumab
    The risk or severity of adverse effects can be increased when Emicizumab is combined with Galcanezumab.
    Eptinezumab
    The risk or severity of adverse effects can be increased when Eptinezumab is combined with Galcanezumab.
    Erenumab
    The risk or severity of adverse effects can be increased when Erenumab is combined with Galcanezumab.
    Esterified estrogens
    Esterified estrogens may increase the thrombogenic activities of Galcanezumab.
    Estetrol
    Estetrol may increase the thrombogenic activities of Galcanezumab.
    Estradiol
    Estradiol may increase the thrombogenic activities of Galcanezumab.
    Estradiol acetate
    Estradiol acetate may increase the thrombogenic activities of Galcanezumab.
    Estradiol cypionate
    Estradiol cypionate may increase the thrombogenic activities of Galcanezumab.
    Estradiol valerate
    Estradiol valerate may increase the thrombogenic activities of Galcanezumab.
    Estriol
    Estriol may increase the thrombogenic activities of Galcanezumab.
    Estrone sulfate
    Estrone sulfate may increase the thrombogenic activities of Galcanezumab.
    Ethinylestradiol
    Ethinylestradiol may increase the thrombogenic activities of Galcanezumab.
    Evolocumab
    The risk or severity of adverse effects can be increased when Evolocumab is combined with Galcanezumab.
    Fanolesomab
    The risk or severity of adverse effects can be increased when Galcanezumab is combined with Fanolesomab.
    Fremanezumab
    The risk or severity of adverse effects can be increased when Fremanezumab is combined with Galcanezumab.
    Gemtuzumab ozogamicin
    The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Galcanezumab.
    Glofitamab
    The risk or severity of adverse effects can be increased when Galcanezumab is combined with Glofitamab.
    Golimumab
    The risk or severity of adverse effects can be increased when Golimumab is combined with Galcanezumab.
    Guselkumab
    The risk or severity of adverse effects can be increased when Guselkumab is combined with Galcanezumab.
    Hepatitis B immune globulin
    The risk or severity of adverse effects can be increased when Hepatitis B immune globulin is combined with Galcanezumab.
    Human cytomegalovirus immune globulin
    The risk or severity of adverse effects can be increased when Human cytomegalovirus immune globulin is combined with Galcanezumab.
    Human immunoglobulin G
    The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Galcanezumab.
    Human Rho(D) immune globulin
    The risk or severity of adverse effects can be increased when Human Rho(D) immune globulin is combined with Galcanezumab.
    Human varicella-zoster immune globulin
    The risk or severity of adverse effects can be increased when Human varicella-zoster immune globulin is combined with Galcanezumab.
    Ibalizumab
    The risk or severity of adverse effects can be increased when Ibalizumab is combined with Galcanezumab.
    Ibritumomab tiuxetan
    The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Galcanezumab.
    Idarucizumab
    The risk or severity of adverse effects can be increased when Idarucizumab is combined with Galcanezumab.
    Inebilizumab
    The risk or severity of adverse effects can be increased when Inebilizumab is combined with Galcanezumab.
    Infliximab
    The risk or severity of adverse effects can be increased when Infliximab is combined with Galcanezumab.
    Inotuzumab ozogamicin
    The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Galcanezumab.
    Ipilimumab
    The risk or severity of adverse effects can be increased when Ipilimumab is combined with Galcanezumab.
    Isatuximab
    The risk or severity of adverse effects can be increased when Galcanezumab is combined with Isatuximab.
    Ixekizumab
    The risk or severity of adverse effects can be increased when Ixekizumab is combined with Galcanezumab.
    Lanadelumab
    The risk or severity of adverse effects can be increased when Galcanezumab is combined with Lanadelumab.
    Lebrikizumab
    The risk or severity of adverse effects can be increased when Lebrikizumab is combined with Galcanezumab.
    Lecanemab
    The risk or severity of adverse effects can be increased when Galcanezumab is combined with Lecanemab.
    Linvoseltamab
    The risk or severity of adverse effects can be increased when Galcanezumab is combined with Linvoseltamab.
    Loncastuximab tesirine
    The risk or severity of adverse effects can be increased when Galcanezumab is combined with Loncastuximab tesirine.
    Maftivimab
    The risk or severity of adverse effects can be increased when Galcanezumab is combined with Maftivimab.
    Margetuximab
    The risk or severity of adverse effects can be increased when Galcanezumab is combined with Margetuximab.
    Marstacimab
    The risk or severity of adverse effects can be increased when Galcanezumab is combined with Marstacimab.
    Mepolizumab
    The risk or severity of adverse effects can be increased when Mepolizumab is combined with Galcanezumab.
    Mirvetuximab soravtansine
    The risk or severity of adverse effects can be increased when Mirvetuximab Soravtansine is combined with Galcanezumab.
    Mogamulizumab
    The risk or severity of adverse effects can be increased when Mogamulizumab is combined with Galcanezumab.
    Mosunetuzumab
    The risk or severity of adverse effects can be increased when Galcanezumab is combined with Mosunetuzumab.
    Natalizumab
    The risk or severity of adverse effects can be increased when Natalizumab is combined with Galcanezumab.
    Necitumumab
    The risk or severity of adverse effects can be increased when Necitumumab is combined with Galcanezumab.
    Nemolizumab
    The risk or severity of adverse effects can be increased when Galcanezumab is combined with Nemolizumab.
    Nipocalimab
    The serum concentration of Galcanezumab can be decreased when it is combined with Nipocalimab.
    Nivolumab
    The risk or severity of adverse effects can be increased when Nivolumab is combined with Galcanezumab.
    Obiltoxaximab
    The risk or severity of adverse effects can be increased when Obiltoxaximab is combined with Galcanezumab.
    Obinutuzumab
    The risk or severity of adverse effects can be increased when Obinutuzumab is combined with Galcanezumab.
    Ocrelizumab
    The risk or severity of adverse effects can be increased when Ocrelizumab is combined with Galcanezumab.
    Odesivimab
    The risk or severity of adverse effects can be increased when Galcanezumab is combined with Odesivimab.
    Ofatumumab
    The risk or severity of adverse effects can be increased when Ofatumumab is combined with Galcanezumab.
    Olaratumab
    The risk or severity of adverse effects can be increased when Olaratumab is combined with Galcanezumab.
    Omalizumab
    The risk or severity of adverse effects can be increased when Omalizumab is combined with Galcanezumab.
    Palivizumab
    The risk or severity of adverse effects can be increased when Palivizumab is combined with Galcanezumab.
    Panitumumab
    The risk or severity of adverse effects can be increased when Panitumumab is combined with Galcanezumab.
    Pembrolizumab
    The risk or severity of adverse effects can be increased when Pembrolizumab is combined with Galcanezumab.
    Penpulimab
    The risk or severity of adverse effects can be increased when Galcanezumab is combined with Penpulimab.
    Pertuzumab
    The risk or severity of adverse effects can be increased when Pertuzumab is combined with Galcanezumab.
    Polatuzumab vedotin
    The risk or severity of adverse effects can be increased when Polatuzumab vedotin is combined with Galcanezumab.
    Ramucirumab
    The risk or severity of adverse effects can be increased when Ramucirumab is combined with Galcanezumab.
    Ranibizumab
    The risk or severity of adverse effects can be increased when Ranibizumab is combined with Galcanezumab.
    Ravulizumab
    The risk or severity of adverse effects can be increased when Ravulizumab is combined with Galcanezumab.
    Raxibacumab
    The risk or severity of adverse effects can be increased when Raxibacumab is combined with Galcanezumab.
    Relatlimab
    The risk or severity of adverse effects can be increased when Galcanezumab is combined with Relatlimab.
    Reslizumab
    The risk or severity of adverse effects can be increased when Reslizumab is combined with Galcanezumab.
    Risankizumab
    The risk or severity of adverse effects can be increased when Galcanezumab is combined with Risankizumab.
    Rituximab
    The risk or severity of adverse effects can be increased when Rituximab is combined with Galcanezumab.
    Romosozumab
    The risk or severity of adverse effects can be increased when Romosozumab is combined with Galcanezumab.
    Rozanolixizumab
    The risk or severity of adverse effects can be increased when Galcanezumab is combined with Rozanolixizumab.
    Sacituzumab govitecan
    The risk or severity of adverse effects can be increased when Sacituzumab govitecan is combined with Galcanezumab.
    Sarilumab
    The risk or severity of adverse effects can be increased when Sarilumab is combined with Galcanezumab.
    Secukinumab
    The risk or severity of adverse effects can be increased when Secukinumab is combined with Galcanezumab.
    Siltuximab
    The risk or severity of adverse effects can be increased when Siltuximab is combined with Galcanezumab.
    Sotatercept
    The risk or severity of adverse effects can be increased when Sotatercept is combined with Galcanezumab.
    Sotrovimab
    The risk or severity of adverse effects can be increased when Galcanezumab is combined with Sotrovimab.
    Spesolimab
    The risk or severity of adverse effects can be increased when Galcanezumab is combined with Spesolimab.
    Sutimlimab
    The risk or severity of adverse effects can be increased when Galcanezumab is combined with Sutimlimab.
    Synthetic Conjugated Estrogens, A
    Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of Galcanezumab.
    Synthetic Conjugated Estrogens, B
    Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Galcanezumab.
    Tafasitamab
    The risk or severity of adverse effects can be increased when Galcanezumab is combined with Tafasitamab.
    Telisotuzumab vedotin
    The risk or severity of adverse effects can be increased when Galcanezumab is combined with Telisotuzumab vedotin.
    Teplizumab
    The risk or severity of adverse effects can be increased when Teplizumab is combined with Galcanezumab.
    Teprotumumab
    The risk or severity of adverse effects can be increased when Teprotumumab is combined with Galcanezumab.
    Tetanus immune globulin, human
    The risk or severity of adverse effects can be increased when Tetanus immune globulin, human is combined with Galcanezumab.
    Tezepelumab
    The risk or severity of adverse effects can be increased when Galcanezumab is combined with Tezepelumab.
    Tildrakizumab
    The risk or severity of adverse effects can be increased when Tildrakizumab is combined with Galcanezumab.
    Tislelizumab
    The risk or severity of adverse effects can be increased when Galcanezumab is combined with Tislelizumab.
    Tisotumab vedotin
    The risk or severity of adverse effects can be increased when Galcanezumab is combined with Tisotumab vedotin.
    Tixagevimab
    The risk or severity of adverse effects can be increased when Galcanezumab is combined with Tixagevimab.
    Tocilizumab
    The risk or severity of adverse effects can be increased when Tocilizumab is combined with Galcanezumab.
    Toripalimab
    The risk or severity of adverse effects can be increased when Galcanezumab is combined with Toripalimab.
    Tralokinumab
    The risk or severity of adverse effects can be increased when Tralokinumab is combined with Galcanezumab.
    Trastuzumab
    The risk or severity of adverse effects can be increased when Trastuzumab is combined with Galcanezumab.
    Trastuzumab deruxtecan
    The risk or severity of adverse effects can be increased when Galcanezumab is combined with Trastuzumab deruxtecan.
    Trastuzumab emtansine
    The risk or severity of adverse effects can be increased when Trastuzumab emtansine is combined with Galcanezumab.
    Tremelimumab
    The risk or severity of adverse effects can be increased when Tremelimumab is combined with Galcanezumab.
    Ublituximab
    The risk or severity of adverse effects can be increased when Ublituximab is combined with Galcanezumab.
    Ustekinumab
    The risk or severity of adverse effects can be increased when Ustekinumab is combined with Galcanezumab.
    Vedolizumab
    The risk or severity of adverse effects can be increased when Vedolizumab is combined with Galcanezumab.
    Vilobelimab
    The risk or severity of adverse effects can be increased when Galcanezumab is combined with Vilobelimab.
    Zanidatamab
    The risk or severity of adverse effects can be increased when Galcanezumab is combined with Zanidatamab.
    Zenocutuzumab
    The risk or severity of adverse effects can be increased when Galcanezumab is combined with Zenocutuzumab.
    Zolbetuximab
    The risk or severity of adverse effects can be increased when Galcanezumab is combined with Zolbetuximab.
    Coverage Restrictions for Get your patient on